American Bio Medica Corp financial data

Symbol
ABMC on OTC
Industry
Pharmaceutical Preparations
Location
122 Smith Road, Kinderhook, NY
State of incorporation
New York
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2023 - Jun 12, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 26.1 % -37.2%
Quick Ratio 10.7 % -28.4%
Debt-to-equity -167 % +37%
Return On Equity -52.1 % -304%
Return On Assets 78 %
Operating Margin -155 % -210%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 48.1M shares 0%
Common Stock, Shares, Outstanding 48.1M shares 0%
Common Stock, Value, Issued 481K USD 0%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 726K USD -63.8%
Cost of Revenue 873K USD -43%
Research and Development Expense 91K USD +4.6%
Selling and Marketing Expense 115K USD -56.3%
General and Administrative Expense 860K USD -23.4%
Operating Income (Loss) -1.12M USD -12.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 1.88M USD
Income Tax Expense (Benefit) 2K USD 0%
Net Income (Loss) Attributable to Parent 850K USD

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 68K USD +300%
Accounts Receivable, after Allowance for Credit Loss, Current 89K USD -35.5%
Inventory, Net 0 USD -100%
Assets, Current 659K USD -36.5%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 659K USD -57.9%
Accounts Payable, Current 572K USD -32.1%
Employee-related Liabilities, Current 32K USD -65.6%
Accrued Liabilities, Current 338K USD
Liabilities, Current 1.12M USD -61.1%
Liabilities 1.12M USD -61.1%
Retained Earnings (Accumulated Deficit) -23.3M USD +3.51%
Stockholders' Equity Attributable to Parent -458K USD +65%
Liabilities and Equity 659K USD -57.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -363K USD -2692%
Net Cash Provided by (Used in) Financing Activities 150K USD
Net Cash Provided by (Used in) Investing Activities 247K USD
Common Stock, Shares Authorized 75M shares 0%
Common Stock, Shares, Issued 48.1M shares 0%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 68K USD +300%
Interest Paid, Excluding Capitalized Interest, Operating Activities 41K USD -10.9%
Deferred Tax Assets, Valuation Allowance 2.68M USD -10.8%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 2.68M USD -10.8%
Property, Plant and Equipment, Gross 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 2.48M USD -9.08%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Additional Paid in Capital 22.4M USD 0%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 167K USD -14.4%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%